Compare Amphastar Pharmaceuticals Inc (AMPH) vs YieldMax Universe Fund of Option Income ETFs (YMAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs YieldMax Universe Fund of Option Income ETFs — how do they compare? Amphastar Pharmaceuticals Inc trades at $20.39 (market cap $863.95M), while YieldMax Universe Fund of Option Income ETFs trades at $7.71. The key difference: Amphastar Pharmaceuticals Inc is trading nearer its 52-week high, YieldMax Universe Fund of Option Income ETFs nearer its low. Which is the better fit depends on your goals.
| AMPH | YMAX | |
|---|---|---|
Market Cap | $863.95M | — |
Sector | Health | Income / Options Overlay |
52-Week High | $30.81 | $13.26 |
52-Week Low | $16.87 | $7.27 |
Enterprise Value | $1.26B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.
Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.
YMAX trades at $7.70, up 1.58% today, with a neutral technical signal and bearish moving averages. Recent news highlights weekly dividend distributions, though a 24/7 Wall Street article on July 14, 2026, notes shrinking payouts and a 1.33% fee structure. The stock lacks disclosed financial ratios, limiting fundamental clarity.
The outlook is mixed, with income appeal from dividends offset by fee concerns and opaque fundamentals. Risks include cost inefficiencies and reliance on market volatility for returns, while technicals suggest near-term consolidation around $8 support/resistance levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About YieldMax Universe Fund of Option Income ETFs
YMAX is an actively managed 'fund of funds' that provides equal-weighted exposure to the full suite of YieldMax option income ETFs. It is designed to generate high current income by aggregating the premiums from various single-stock and thematic covered call strategies, offering a diversified approach to high-yield option investing.
Read more on YMAX →
